Aptose biosciences Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Aptose biosciences Contact Number

Contact :: Aptose Biosciences Inc. (APTO)

Just Now Aptose.com Show details

858.926.2730Executive Headquarters. 12770 High Bluff Drive, Suite 120 San Diego, CA 92130, USA Tel: 858.926.2730

Category: Contact SupportShow more

Aptose Biosciences Inc. (APTO)

3 hours ago Aptose.com Show details

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address the unmet clinical need in chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia …

Category: Contact NumberShow more

Aptose Biosciences Crunchbase Company Profile & …

8 hours ago Crunchbase.com Show details

416-798-1200Contact Email [email protected] Phone Number 416-798-1200 Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles.

Founded: 1986

Category: Contact NumberShow more

Aptose Biosciences Inc. Profile SEDAR

3 hours ago Sedar.com Show details

650 718-5028Aptose Biosciences Inc. Mailing Address: 251 Consumers Road Suite 1105 Toronto, Ontario M2J 4R3: Head Office Address: 251 Consumers Road Suite 1105 Toronto, Ontario M2J 4R3: Contact Name: Gregory K. Chow: Principal Regulator: Ontario: Business e-mail address: [email protected]aptose.com: Short Form Prospectus Issuer: Yes: Telephone Number: 650 718-5028

Contact Name: Gregory K. Chow
Principal Regulator: Ontario

Category: Contact NumberShow more

Aptose Biosciences, Inc. Email Format aptose.com Emails

5 hours ago Rocketreach.co Show details

Aptose Biosciences, Inc. uses 1 email formats: 1. first_initial [email protected]aptose.com (100.0%). Enter a name to find & verify an email >>> Rocketreach finds email, phone & social media for 450M+ professionals.

Category: Contact NumberShow more

Careers :: Aptose Biosciences Inc. (APTO)

Just Now Aptose.com Show details

Contact; Careers. We Are Aptose Biosciences. Our team is dedicated to building a comprehensive drug pipeline and clinical development programs focused on targeted therapeutics. We are always on the lookout for innovative and passionate candidates to join us in the fight against cancer.

Category: Contact NumberShow more

APTOSE BIOSCIENCES INC.

4 hours ago Aptose.com Show details

843-20-0016Commission file number 001-3200 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada (State or other jurisdiction of incorporation or organization) 98-1136802 (I.R.S. Employer Identification No.) 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 (Address of principal executive offices) 647-479-9828

Category: Contact NumberShow more

About :: Aptose Biosciences Inc. (APTO)

8 hours ago Aptose.com Show details

A Pipeline to Change Conventional Anti-Cancer Therapies. At Aptose Biosciences, we are building a pipeline of novel and targeted oncology therapies with the potential to serve specific populations of cancer patients. Our pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of conventional anti-cancer

Category: Contact NumberShow more

Aptose Biosciences Inc. (Form: DEF 14A, Received: 04/21

4 hours ago Content.edgar-online.com Show details

843-21-0026To request a printed copy of the proxy materials, please contact your broker, if you are a non-registered Shareholder, or if you are a registered Shareholder, contact our Chief Financial Officer at Aptose Biosciences Inc., Suite 120, 12770 High Bluff Drive, San Diego, California, telephone: 858-926-2730.

Category: Contact NumberShow more

Aptose Biosciences Inc. (Form: 8K, Received: 06/01/2021

1 hours ago Content.edgar-online.com Show details

843-21-0039Aptose Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Canada: 001-32001: 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) For further information, please contact:

Category: Contact NumberShow more

Aptose Biosciences, Inc. to Host Earnings Call

2 hours ago Finance.yahoo.com Show details

NEW YORK, NY / ACCESSWIRE / March 23, 2021 / Aptose Biosciences, Inc. (NASDAQ:APTO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 23

Category: Contact NumberShow more

Aptose Biosciences Inc. (Form: 8K, Received: 05/04/2021

1 hours ago Content.edgar-online.com Show details

843-21-0031Aptose will host a conference call to discuss results for the quarter ended March 31, 2021 today, Tuesday, May 4, 2021 at 4:30 PM ET. Participants can access the conference call by dialing 1-844-882-7834 (North American toll-free number) and 1-574-990-9707 (international/toll number) and using conference ID # 2788133.

Category: Contact NumberShow more

Aptose Reports Results for the Fourth Quarter and Full

9 hours ago Aptose.com Show details

844-882-7834Aptose will host a conference call to discuss results for the year and quarter ended December 31, 2020 today, Tuesday, March 23, 2021 at 5:00 PM ET. Participants can access the conference call by dialing 1-844-882-7834 (North American toll-free number) and 1-574-990-9707 (international/toll number) and using conference ID # 9179487.

Category: Contact NumberShow more

APTO Aptose Biosciences Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021:

Category: Contact NumberShow more

News & Events :: Aptose Biosciences Inc. (APTO)

4 hours ago Aptose.com Show details

View IR Calendar. Email Alerts. Sign up for email alerts for Press Releases & SEC Filings. Sign Up

Category: Contact NumberShow more

Donald R. Wilson, Jr. Net Worth, Biography & Insider

8 hours ago Insidertrades.com Show details

858-926-2730The corporate mailing address for Mr. Wilson, Jr. and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]aptose.com.

Category: Contact NumberShow more

A Study of APTO253 in Patients With Relapsed or

7 hours ago Clinicaltrials.gov Show details

713-745-4642Contact: Robin Thomas, RN, BSN 713-745-4642 [email protected] Contact: Mary Kelly, RN 713-794-4656 [email protected] Principal Investigator: Maro …

Category: Contact NumberShow more

Aptose Biosciences, Inc. (APTO) Company Profile & Facts

4 hours ago Finance.yahoo.com Show details

See the company profile for Aptose Biosciences, Inc. (APTO) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and

Category: Contact NumberShow more

Aptose Bioscns (APTO) Recent Earnings

8 hours ago Earningswhispers.com Show details

Aptose Bioscns (APTO) reported a 2nd Quarter June 2021 loss of $0.15 per share on revenue of $0.0 million. The consensus estimate was a loss of $0.18 per share. Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology.

Category: Contact NumberShow more

Biotech catalyst calendars and drug pipelines

Just Now Biopharmcatalyst.com Show details

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021:

Category: Tech SupportShow more

Aptose Presents Highlights from EHA During Corporate

6 hours ago Ca.finance.yahoo.com Show details

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET, in …

Category: Contact NumberShow more

Hedge Funds Are Crazy About Aptose Biosciences Inc (APTO)

2 hours ago Finance.yahoo.com Show details

The number of long hedge fund positions inched up by 2 recently. Aptose Biosciences Inc (NASDAQ:APTO) was in 23 hedge funds' portfolios at the end of …

Category: Contact NumberShow more

Buy Aptose Biosciences Stocks and Shares ️ Forex Suggest

4 hours ago Forexsuggest.com Show details

Aptose Biosciences Inc. trades on the Toronto Stock Exchange (TSX), where investors can buy shares under the stock symbol –APS. Data from the company’s 2019 financial analysis shows a net increase in cash equivalents to US Dollar 5.3 million, up from US Dollar 4.4 million on the previous year.

Category: Contact NumberShow more

Aptose Reports Results for the Fourth Quarter and Full

3 hours ago Finance.yahoo.com Show details

For further information, please contact: Aptose Biosciences Inc.LifeSci Advisors, LLCGreg Chow Dan Ferry, Managing DirectorExecutive …

Category: Contact NumberShow more

Aptose Biosciences Establishes New AtTheMarket Facility

2 hours ago Finance.yahoo.com Show details

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Category: Contact NumberShow more

Aptose Initiates Dosing of CG806 in Patients with Acute

6 hours ago Finance.yahoo.com Show details

Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mgSAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ

Category: Contact NumberShow more

Aptose Presents Highlights from EHA During Corporate

5 hours ago Investingnews.com Show details

Aptose Biosciences Inc. a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a …

Category: Contact NumberShow more

Checking in with Aptose Biosciences ($APTO) CEO Dr

4 hours ago Biopub.co Show details

Aptose CEO Rice (R) with CEO Joo Jung-myeong of Crystal Genomics, Seoul, 2018. A milestone payment ceremony at CG, from which Aptose licensed malignancy-associated pan-tyrosine kinase inhibitor CG’806 for global development ex-Korea. As we noted in our recent JPM coverage, Aptose plans to submit to the FDA an investigational new drug

Category: Contact NumberShow more

Aptose Reports Results for the First Quarter 2021

2 hours ago Finance.yahoo.com Show details

For further information, please contact: Aptose Biosciences Inc. LifeSci Advisors, LLCSusan Pietropaolo Dan Ferry, Managing DirectorInvestor Relations …

Category: Contact NumberShow more

Aptose Presents Highlights from ASH and Corporate Update Event

2 hours ago Investingnews.com Show details

Aptose Biosciences Inc. today released highlights from a corporate update event held on Sunday, December 6 th in conjunction with participation at …

Category: Contact NumberShow more

Aptose Biosciences Inc. (APTO): The stock medium term

9 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 88.95 million. APTO does have institutional investors; and they hold 35.10% of the stock. Aptose Biosciences Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 57,199 shares.

Category: Contact NumberShow more

Aptose Presents Highlights From Corporate Event At ASH

6 hours ago Globenewswire.com Show details

Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253. December 07, 2019 11:00 ET Source: Aptose Biosciences, Inc.

Category: Contact NumberShow more

What Are Analysts and Indicators Saying About Aptose

Just Now Baxterreport.com Show details

APTO – Aptose Biosciences Inc. Stock Earnings Estimates. Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is …

Category: Contact NumberShow more

Aptose to Present at September Investor Conferences

3 hours ago Investingnews.com Show details

Aptose Biosciences Inc. a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will

Category: Contact NumberShow more

Aptose to Hold Corporate Update Friday, June 11th

8 hours ago Investingnews.com Show details

Aptose Biosciences Inc. a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will

Category: Contact NumberShow more

Aptose Enters Into License Agreement With CrystalGenomics

Just Now Globenewswire.com Show details

Toronto, Ontario, CANADA. SAN DIEGO and SEOUL, South Korea, June 14, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that they have entered into a license

Category: Contact NumberShow more

Aptose Biosciences Establishes New AtTheMarket Facility

5 hours ago Nasdaq.com Show details

020-05-05--Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, …

Category: Contact NumberShow more

Aptose Biosciences : Corporate Presentation at Cantor

4 hours ago Marketscreener.com Show details

Aptose Biosciences Inc. published this content on 27 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 September 2021 05:21:06 UTC.

Category: Contact NumberShow more

ABRAMSON HERBERT SC 13G/A Filing Concerning APTO on 2020 …

1 hours ago Whalewisdom.com Show details

020-02-040001178913-20-000268.txt : 20200204 0001178913-20-000268.hdr.sgml : 20200204 20200204104906 accession number: 0001178913-20-000268 conformed submission type: sc 13g/a public document count: 1 filed as of date: 20200204 date as of change: 20200204 subject company: company data: company conformed name: aptose biosciences inc. central index key: 0000882361 …

Category: Contact NumberShow more

How Is Aptose Biosciences Inc.(NASDAQ: APTO) Is Expected

9 hours ago Marketingsentinel.com Show details

Aptose Biosciences Inc. (NASDAQ:APTO)’s Major holders. Insiders own 5.09% of the company shares, while shares held by institutions stand at 59.69% with a share float percentage of 62.89%. Investors are also buoyed by the number of investors in a company, with Aptose Biosciences Inc. having a total of 83 institutions that hold shares in the

Category: Contact NumberShow more

What Analysts Were Expecting After Aptose Biosciences Inc

8 hours ago Stocksregister.com Show details

According to the data, the short interest in Aptose Biosciences Inc. (APTO) stood at 3.45% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 3.36 million. The stock has fallen by -47.49% since the beginning of the year, thereby showing the potential of a further growth.

Category: Contact NumberShow more

How to buy Aptose Biosciences stock (NASDAQ: APTO) stock

1 hours ago Finder.com Show details

However Aptose Biosciences's short interest can also be evaluated against the total number of Aptose Biosciences shares, or, against the total number of tradable Aptose Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – …

Category: Contact NumberShow more

Aptose Reports Results for the Fourth Quarter and Full

4 hours ago Investingnews.com Show details

Aptose will host a conference call to discuss results for the year and quarter ended December 31, 2020 today, Tuesday, March 23, 2021 at 5:00 PM ET. Participants can access the conference call by

Category: Contact NumberShow more

Aptose Expands Senior Leadership Team Eminetra Canada

2 hours ago Eminetracanada.com Show details

About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and …

Category: Contact NumberShow more

Aptose Biosciences Announces Exclusive License Agreement

4 hours ago Globenewswire.com Show details

647-479-9828Aptose Biosciences Greg Chow, CFO 647-479-9828 Email: [email protected]aptose.com SMP Communications Susan Pietropaolo 201-923-2049 [email protected]

Category: Contact NumberShow more

Aptose Biosciences : Corporate Presentation June 2021

Just Now Marketscreener.com Show details

Aptose Biosciences Inc. published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 13:50:04 UTC.

Category: Contact NumberShow more

Aptose to Hold Corporate Update Sunday, December 6th

1 hours ago Investingnews.com Show details

Aptose Biosciences Inc. a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of biotechnology company is aptose Biosciences?

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Who is the CEO of apto Biosciences?

"Our recent clinical experience has confirmed that luxeptinib is an active drug in several indications across both myeloid and lymphoid malignancies, which is consistent with our hypotheses from our broad portfolio of preclinical work," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

How are aptose drug candidates designed to work?

Our drug candidates have been designed to provide safe single agent efficacy in multiple adjacent indications, as well as enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

What are the clinical status of aptose's luxeptinib?

The event is focused on the current clinical status of luxeptinib, Aptose's oral, first-in-class FLT3 and BTK kinase inhibitor currently in two Phase 1 a/b trials, one trial in patients with relapsed or refractory acute myeloid leukemia (AML), and the other trial in patients with relapsed or refractory B cell malignancies.

Popular Brands

Amazon
Abbvie
Aia
Asml
Apple
Att
Amgen
Adobe
Aptar
Acc
Adidas
Aak
Aes
Asx